Nathan Higginson-Scott

Chief Technology Officer and SVP, Drug Creation at Seismic Therapeutic

Speaker

Nathan has been creating innovative biologics drugs and drug technologies for over 15 years in both academia and industry.

Prior to joining Seismic, he served as VP of Biotherapeutics at Pandion Therapeutics where he played a pivotal role in growing Pandion from its earliest days in 2017 through several successful large financing rounds, an upsized IPO and the companies ultimate acquisition by Merck in 2021 for $1.85bn. Under Nathan’s leadership, Pandion’s Biotherapeutics group developed the tissue targeting TALON platform and created PT101, a now clinical stage TReg agonist.

Prior to Pandion, Nathan held various positions at Pfizer where he co-invented a proprietary bispecific platform, led an antibody optimization group, and led numerous technology development, drug discovery and preclinical stage projects across a number of therapeutic areas including inflammation and immunology. Nathan also worked at Google[x] to help launch Verily Life Sciences where he played a key role in the development of antibody-based capabilities designed to support a diagnostic nanoparticle platform.

Nathan believes that organizations can only truly succeed when people feel safe in bringing all of who they are to work. He co-founded the MA chapter of a Pfizer Colleague Resource Group for LGBTQ+ employees and allies. And drove Pandion’s participation in Boston Pride. Most recently Nathan volunteers time every week as a suicide and crisis intervention counsellor for The Trevor Project supporting LGBTQ+ youth in crisis.

Nathan began his career in antibody technology and molecular immunology at Imperial College London on a prestigious Wellcome Trust grant, where Nathan’s Ph.D. focused on innovative methods for developing bi-paratopic antibodies using phage display.